Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.29M$2.29Mderived+13.5% vs Q4 2015 Net Income-$352.77K-$352.77KderivedN/M vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,420,123+31.3% Operating Incomederived-$367,950N/M Operating Cash Flowderived-$415,444N/M Free Cash Flowderived-$508,461N/M Margins · derivedGross margin61.9%+8.4 pt vs Q4 2015
Operating margin-16.1%+4.5 pt vs Q4 2015
Net margin-15.4%+5.1 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 8, 2017 · 67 d after period end